<DOC>
	<DOCNO>NCT00528385</DOCNO>
	<brief_summary>The main purpose study find whether addition aldosterone antagonist , spironolactone dual renin-angiotensin-aldosterone system blockade involve angiotensin convert enzyme inhibitor AT-1 angiotensin II receptor blocker lead reduction proteinuria , main prognostic marker chronic kidney disease progression .</brief_summary>
	<brief_title>Optimalization Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System</brief_title>
	<detailed_description>The renin-angiotensin-aldosterone system ( RAAS ) play important role progression chronic kidney disease ( CKD ) , inhibition RAAS angiotensin-converting enzyme inhibitor ( ACEI ) angiotensin II type 1 receptor blocker ( ARB ) may retard CKD progression . Dual pharmacological blockade RAAS ACEI ARB recommend standard renoprotective management least patient nondiabetic proteinuric CKD . However , neither ACEI ARB , even high dos concomitant usage , abrogate progression CKD completely . Innovative approach need keep patient CKD dialysis . Additional blockade aldosterone pathway may prove beneficial therapeutic concept.Aldosterone , final effector RAAS play significant role pathogenesis CKD independently angiotensin II direct cellular action . This include promote inflammatory response , endothelial dysfunction , fibrosis increase plasminogen activator inhibitor ( PAI-1 ) transform growth factor beta-1 ( TGF-beta-1 ) expression stimulation reactive oxygen species.A number observation suggest nongenomic vasoconstrictor action aldosterone lead raise arterial glomerular capillary pressure.Given fact additional administration aldosterone antagonist combination treatment ACEI ARB , call triple RAAS blockade may provide additional renal protection . To shed light issue , perform randomise open control study evaluate influence triple RAAS therapy surrogate marker kidney injury , i.e . proteinuria , marker tubular involvement kidney fibrosis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>chronic kidney disease stable proteinuria 300 mg/24 hour ( variation 25 % last 6 month ) normal slightly impaired stable renal function define serum creatinine level 1.7 mg/dl ( eGFR &gt; 45 ml/min ) nephrotic syndrome steroid immunosuppressive treatment minimum six month study diabetes mellitus potassium serum level &gt; 5.1 mEq/L albumin serum level &lt; 2.0mg/dL creatinine serum level &gt; 2 mg/dl current diagnosis heart failure New York Heart Association ( NYHA ) Class IIIV clinically significant valvular heart disease second third degree heart block without pacemaker history hypertensive encephalopathy , cerebrovascular accident transient ischemic cerebral attack history myocardial infarction , unstable angina pectoris , coronary bypass surgery , percutaneous coronary intervention history malignancy include leukemia lymphoma ( basal cell skin carcinoma ) within past five year pregnant nursing woman surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug . history alcohol abuse NSAID abuse ( 2 dos per week ) know suspected contraindication study medication , include history allergy ACE inhibitor , AT1 receptor blocker aldosterone antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Proteinuria</keyword>
	<keyword>Renin-Angiotensin-Aldosterone System</keyword>
	<keyword>Aldosterone Antagonists</keyword>
</DOC>